Verrica Pharmaceuticals Inc (VRCA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has a cash flow conversion efficiency ratio of -2.154x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.28 Million) by net assets ($4.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Verrica Pharmaceuticals Inc (VRCA) market capitalisation for the company's overall valuation and market capitalisation.
Verrica Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verrica Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore VRCA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeil Pharm
KO:002620
|
0.001x |
|
Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd
KQ:333430
|
0.030x |
|
Island Pharmaceuticals Ltd
AU:ILA
|
-0.237x |
|
Atrium Real Estate Investment Trust
KLSE:5130
|
0.029x |
|
Keum Kang Steel Co. Ltd
KQ:053260
|
-0.014x |
|
Xlife Sciences AG
SW:XLS
|
-0.002x |
|
Amanat Acquisition Corp Class A Ordinary Shares
NASDAQ:AMAN
|
N/A |
|
Klevo Rewards Limited
AU:KLV
|
N/A |
Annual Cash Flow Conversion Efficiency for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Verrica Pharmaceuticals Inc from 2016 to 2025. View VRCA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.74 Million | $-17.63 Million | -0.712x | -111.53% |
| 2024-12-31 | $-9.86 Million | $-60.93 Million | 6.179x | +416.56% |
| 2023-12-31 | $19.76 Million | $-38.58 Million | -1.952x | -319.00% |
| 2022-12-31 | $40.03 Million | $-18.65 Million | -0.466x | +44.93% |
| 2021-12-31 | $32.60 Million | $-27.58 Million | -0.846x | +7.62% |
| 2020-12-31 | $32.99 Million | $-30.21 Million | -0.916x | -117.23% |
| 2019-12-31 | $65.02 Million | $-27.41 Million | -0.422x | -110.92% |
| 2018-12-31 | $89.43 Million | $-17.87 Million | -0.200x | -130.71% |
| 2017-12-31 | $-7.04 Million | $-4.58 Million | 0.651x | +7.64% |
| 2016-12-31 | $-2.66 Million | $-1.61 Million | 0.605x | -- |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more